Impact of Heart Failure Team on Inpatient Rapid Sequencing of Heart Failure Therapy

The management of heart failure (HF) has undergone a paradigm shift from conventional stepwise methods of initiation and the up-titration of HF therapy towards an early, more intensive initiation of pharmacotherapy to improve the prognosis. The aim of this study was to compare the outcomes of patien...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiovascular development and disease Vol. 12; no. 2; p. 50
Main Authors: Zhou, Zhongrui, Kardas, Khalid, Gue, Ying Xuan, Najm, Ali, Tirawi, Anas, Goode, Rachel, Frodsham, Robert, Kavanagh, Rory, Rao, Archana, Dobson, Rebecca, Wright, David, Kahn, Matthew
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01.02.2025
MDPI
Subjects:
Acute coronary syndromes
Age groups
Cardiac patients
Cardiomyopathy
Cardiovascular agents
Cardiovascular disease
Drug dosages
Ejection fraction
Etiology
Evidence-based medicine
failure
Health aspects
Heart
Heart failure
Hospitals
inpatient
Ischemia
Length of stay
Medical prognosis
Mortality
Older people
Patients
Quality of life
rapid
sequencing
team
United Kingdom
United Kingdom
United Kingdom > UK
rapid
team
failure
inpatient
heart
sequencing
ISSN:2308-3425, 2308-3425
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The management of heart failure (HF) has undergone a paradigm shift from conventional stepwise methods of initiation and the up-titration of HF therapy towards an early, more intensive initiation of pharmacotherapy to improve the prognosis. The aim of this study was to compare the outcomes of patients at the Liverpool Heart and Chest Hospital (LHCH), with new diagnosis of HF, who were reviewed by the inpatient heart failure team (HFT), compared to patients that were not reviewed. A retrospective review of the electronic records of patients admitted with a new diagnosis of HF to the LHCH from May to December 2023 was performed. Admission drugs were similar, apart from betablockers, which were more frequent in the non-HFT group (58% vs. 24.2%; p = 0.002). The length of inpatient stay was longer in the HFT group (median 5.5 days vs. 3 days; p = 0.001) and more likely to be on all four pillars of HF medical therapy (96.8% vs. 0; p < 0.001) within 30 days of discharge. The 30-day and 6-month mortality outcomes were not significantly different. Patients reviewed by the HFT were significantly more likely to receive the four pillars of HF therapy within 30 days of their diagnosis compared to their counterparts at the expense of a longer length of stay.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
ISSN:2308-3425
2308-3425
DOI:10.3390/jcdd12020050